What is Emblaveo and what is it used for?

Emblaveo is an antibiotic medicine that contains two active substances aztreonam and avibactam.

• Aztreonam belongs to the group of antibiotics called “monobactams”. It can kill certain types of bacteria (so-called Gram-negative bacteria).

• Avibactam is a “beta-lactamase inhibitor” that helps aztreonam kill some bacteria that it cannot kill on its own.

Emblaveo is used in adults in the UK for the treatment of the following infections:

• complicated bacterial infections of the abdomen (stomach and gut), where the infection has spread into abdominal cavity (space within the abdomen).

• hospital-acquired pneumonia (a bacterial infection of the lungs that is picked up in hospitals), including ventilator-associated pneumonia (pneumonia that develops in patients on a machine called a ventilator to help them breathe).

• complicated (difficult to treat as it has spread to other parts of the body or the patient has other conditions) urinary tract infections, including pyelonephritis (kidney infection).

• infections caused by Gram-negative bacteria that other antibiotics may not be able to kill.

Reference Information

If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Emblaveo visit the electronic Medicines Compendium (eMC).

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.